A new sustained-release microsphere formulation of exenatide, known as DA-3091, has shown promise in managing obesity, diabetes, and nonalcoholic fatty liver disease, offering effective metabolic control with less frequent dosing, potentially improving patient compliance
A negative one often means the substance stays off the list
For insulin resistance and prediabetes, steadier post-meal blood sugar supports the broader plan, as outlined by the NIDDK overview of obesity medications
Take this tablet as directed by your doctor
I expected this as I have a very healthy BMI
Many describe it as similar to the feeling you might get from slight motion sickness or eating too quickly